TY - JOUR
T1 - 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
AU - Sakurai, Yasuteru
AU - Ngwe Tun, Mya Myat
AU - Kurosaki, Yohei
AU - Sakura, Takaya
AU - Inaoka, Daniel Ken
AU - Fujine, Kiyotaka
AU - Kita, Kiyoshi
AU - Morita, Kouichi
AU - Yasuda, Jiro
PY - 2021/3/19
Y1 - 2021/3/19
N2 - © 2021 Elsevier Inc. The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19.
AB - © 2021 Elsevier Inc. The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85100699280&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2021.01.091
DO - 10.1016/j.bbrc.2021.01.091
M3 - Article
VL - 545
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
ER -